Shares of Labcorp Holdings Inc. LH inched 0.34% higher to $229.92 Monday, on what proved to be an all-around mixed trading ...

The Federal Circuit rejected Laboratory Corporation of America Holdings’ challenge of a competitor’s fetal DNA test patent ...

The Federal Circuit on Monday, January 6, rejected Labcorp's argument that the Patent Trial and Appeal Board erred in its ...

The U.S. Attorney's Office said the two allegedly delayed certain laboratory tests by Caris Life Sciences between March 2012 ...

LabCorp and University Health System settle on $388,667 for alleged False Claims Act violations related to Medicare billing.

Labcorp Holdings Inc. LH, or Labcorp, is targeting high-growth areas as part of its expansion. By partnering with health systems and regional local laboratories, the company is leveraging science and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Fortrea, a recent Labcorp spin-off, is poised for recovery with strong bookings, industry inflection, and activist interest, ...

Labcorp Holdings' (NYSE:LH) stock up by 5.0% over the past three months. However, we decided to study the company's mixed-bag of fundamentals to assess what this could mean for future share prices, as ...

University Health System and Labcorp pay $388,667 to resolve False Claims Act allegations of improper billing to Medicare for lab tests.

Labcorp Holdings Inc. closed $18.84 short of its 52-week high ($247.99), which the company achieved on November 11th.